Enliven Therapeutics (NASDAQ:ELVN) Reaches New 52-Week High After Analyst Upgrade

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) hit a new 52-week high during mid-day trading on Tuesday after The Goldman Sachs Group raised their price target on the stock from $59.00 to $67.00. The Goldman Sachs Group currently has a buy rating on the stock. Enliven Therapeutics traded as high as $54.29 and last traded at $53.9850, with a volume of 303573 shares. The stock had previously closed at $51.67.

A number of other analysts have also weighed in on ELVN. Stifel Nicolaus increased their target price on Enliven Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday. JonesTrading upped their price target on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Guggenheim initiated coverage on shares of Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $70.50.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total value of $263,588.40. Following the completion of the sale, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $2,233,800. This represents a 10.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the transaction, the director directly owned 51,884 shares in the company, valued at $1,792,073.36. The trade was a 16.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 26,018 shares of company stock worth $1,113,888. 3.00% of the stock is owned by insiders.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. KBC Group NV bought a new position in Enliven Therapeutics during the 1st quarter worth about $38,000. FNY Investment Advisers LLC bought a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at about $126,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the period. Finally, Quantbot Technologies LP lifted its position in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Stock Up 5.1%

The stock’s 50 day moving average price is $44.88 and its 200-day moving average price is $36.64. The stock has a market capitalization of $3.31 billion, a P/E ratio of -32.53 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. Analysts anticipate that Enliven Therapeutics, Inc. will post -1.57 earnings per share for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.